Company profile: Virpax Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of intranasal and topical therapeutics for pain, epilepsy, and viral inhibition, including: Probudur, a single-injection liposomal bupivacaine for extended post-operative pain; Envelta, intranasal enkephalin for acute/chronic and cancer pain; NobrXiol, intranasal CBD for rare pediatric epilepsy; AnQlar, intranasal spray to inhibit influenza/SARS-CoV-2; and Epoladerm, topical diclofenac spray film for osteoarthritis.
Products and services
- Envelta: A Molecular Envelope Technology-based intranasal enkephalin product architects management of acute and chronic pain, including cancer-related pain
- Epoladerm: A spray-film topical diclofenac product engineers osteoarthritis pain control, engineered for easy application and sustained release
- Probudur: A liposomal bupivacaine product delivers post-operative pain management via a single injection, producing extended pain relief
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Virpax Pharmaceuticals
Alexza
HQ: United States
Website
- Description: Provider of inhaled therapeutics for acute and intermittent conditions, featuring commercial ADASUVE (loxapine) for acute agitation in adults with schizophrenia or bipolar disorder, and developing Staccato inhalation candidates: alprazolam for epileptic seizures, apomorphine for OFF episodes in Parkinson’s disease, and granisetron for cyclic vomiting syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alexza company profile →
MedinCell
HQ: France
Website
- Description: Provider of injectable slow-release drug expertise.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MedinCell company profile →
Haselmeier
HQ: Germany
Website
- Description: Provider of innovative self-injection devices, including pen injectors and other systems for self injection, featuring proprietary designs, technology and intellectual property. With over four decades of medical device experience, the company offers a world-class design and development team working in compliance with regulatory requirements.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Haselmeier company profile →
CeQur
HQ: Switzerland
Website
- Description: Provider of wearable insulin delivery solutions for people with diabetes, including the CeQur Simplicity insulin patch that delivers mealtime bolus insulin via a small, flexible cannula without injections. Offers a Patient Starter Kit with patches and a reusable inserter, the CeQur Cares support program, and the CeQur Simplicity Copay Savings Card. Works with physicians and centers to bring technology to patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CeQur company profile →
Biocorp Systems
HQ: France
Website
- Description: Provider of medical devices and drug delivery systems; a pharmaceutical company that develops, manufactures, and markets these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocorp Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Virpax Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Virpax Pharmaceuticals
2.2 - Growth funds investing in similar companies to Virpax Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Virpax Pharmaceuticals
4.2 - Public trading comparable groups for Virpax Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →